Breakthrough in Small Cell Lung Cancer Therapy: The Role of IFITM3 in Enhancing Immunotherapy Response

Recent research presented at the 2025 World Conference on Lung Cancer has identified interferon-induced transmembrane protein 3 (IFITM3) as a crucial factor influencing the effectiveness of immunotherapy in small cell lung cancer (SCLC). SCLC is known for its low expression of major histocompatibility complex class I (MHC-I), which hampers immune system recognition and attack. The new findings suggest that IFITM3 can improve this recognition by activating NLRC5—a key transcriptional regulator—leading to increased MHC-I expression, enhanced antigen presentation, and greater infiltration of cytotoxic CD8+ T cells into tumors.

Dr. Xinyu Liu from Shanghai Pulmonary Hospital noted that their team discovered a strong correlation between IFITM3 levels and MHC-I expression across various patient cohorts. Overexpression of IFITM3 was shown to stimulate antigen presentation pathways and promote immune cell infiltration, ultimately predicting better progression-free survival in patients undergoing chemoimmunotherapy. Additionally, the research highlighted a promising compound, ethyl gallate (EG), which can induce IFITM3 expression and sensitize tumors to PD-1 checkpoint blockade in preclinical models.

These insights indicate that pharmacologically boosting IFITM3 could represent a new strategy to overcome resistance to immunotherapy in SCLC. Future clinical studies are needed to validate IFITM3 as a biomarker for treatment response and explore its potential as a therapeutic target. The research underscores the importance of understanding tumor immunogenicity and paves the way for improved treatment outcomes in this aggressive cancer type.